AbbVie (ABBV) Reports ABBV-951Showed Improvement in Controlling Motor Fluctuations Compared to Oral Levodopa/Carbidopa Medication in Pivotal Phase 3 Trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. BRZE
2. TTAN
3. CHYM
4. USO
5. QCOM
6. IRT
7. ASO
8. AAPL
9. NTHI
10. SPY

Go back to AbbVie (ABBV) Reports ABBV-951Showed Improvement in Controlling Motor Fluctuations Compared to Oral Levodopa/Carbidopa Medication in Pivotal Phase 3 Trial
AbbVie (NYSE: ABBV) Delayed: 249.00 +0.22 (0.09%)
Previous Close $248.78    52 Week High $68.12 
Open $247.73    52 Week Low $50.71 
Day High $250.96    P/E 54.01 
Day Low $246.77    EPS $4.61 
Volume 1,112,112